文献速递小儿眼科与斜弱视

评估Nanodropper装置用于儿童散瞳与睫状肌麻痹效果的随机试验

Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children.
PubMed 文献 · Ophthalmology · 2022-10-22

这项前瞻性随机试验在50例儿童中比较了Nanodropper微量滴眼瓶(10.4μl)与标准50μl滴眼液在散瞳和睫状肌麻痹上的效果。结果显示,散瞳后最大瞳孔直径达到非劣效性,但等效球镜度和瞳孔收缩百分比未达到严格非劣效性;作者认为各主要结局的微小差异无临床意义,微量滴眼液有望在保持疗效的同时减少医疗浪费和药物毒性。

要点

  • 散瞳后最大瞳孔直径在Nanodropper组达到非劣效性(均值-0.01mm,95%CI -0.20至-0.03)。
  • 等效球镜度和瞳孔收缩百分比未达到严格非劣效性,但差异微小且无临床意义。
  • 作者结论认为微量滴眼液有潜力在保持疗效的同时减少不必要的医疗浪费和药物毒性。

核心结论

  • 在儿童中,使用微量滴眼适配器给药在散瞳方面达到严格非劣效性,但在睫状肌麻痹和瞳孔收缩百分比方面未达到严格非劣效性;然而各主要结局的微小差异无临床意义。
  • 作者结论认为,微量滴眼液有潜力在保持治疗效果的同时减少不必要的医疗浪费和药物毒性。

研究设计与样本

  • 前瞻性随机试验,纳入50例在加利福尼亚大学旧金山分校小儿眼科诊所计划接受常规散瞳的儿童患者,每例提供1眼为干预组(Nanodropper)和1眼为对照组(标准治疗)。
  • 散瞳使用1%环喷托酯、1%托吡卡胺和2.5%去氧肾上腺素各1滴;散瞳前和散瞳后30分钟进行验光和瞳孔测量。
  • 采用非劣效性分析评估散瞳前后等效球镜度、瞳孔收缩百分比和散瞳后最大瞳孔直径的变化。

主要发现

  • 共纳入50例患者的100只眼,平均年龄9±3岁。
  • 控制基线测量后,散瞳后等效球镜度在Nanodropper组多0.05D(95%CI -0.28至0.37D),未达到非劣效性。
  • 散瞳后最大瞳孔直径在Nanodropper组较低(均值-0.01mm,95%CI -0.20至-0.03mm),达到非劣效性。
  • 散瞳后瞳孔收缩百分比在Nanodropper组多0.57个百分点(95%CI -1.38至2.51个百分点),未达到非劣效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the noninferiority of 10.4 μl of eye drops eluted with a commercially available eye drop adapter, the Nanodropper (Nanodropper, Inc), on pupillary dilation and cycloplegia in children compared with the standard of care (SOC), 50 μl of eye drops. DESIGN: Prospective randomized trial. PARTICIPANTS: Pediatric patients scheduled for routine pupillary dilation at the University of California, San Francisco, at the Pediatric Ophthalmology Clinic were enrolled. Each participant provided 1 eye for the intervention group (Nanodropper) and 1 eye for the control group (SOC). METHODS: Participants were randomized to receive small-volume dilating drops in 1 eye (Nanodropper) and SOC dilating drops in the other eye. Dilation was performed using 1 drop each of 1% cyclopentolate, 1% tropicamide, and 2.5% phenylephrine. Refraction and pupillometry were obtained before and 30 minutes after dilation. A noninferiority analysis was performed to assess change from before to after dilation in spherical equivalent and in pupil constriction percentage and maximum pupil diameter after dilation. MAIN OUTCOME MEASURES: Spherical equivalent, maximum pupil diameter, and pupil constriction percentage. RESULTS: One hundred eyes of 50 patients were included, with a mean ± standard deviation age of 9 ± 3 years. After controlling for baseline measurements, the spherical equivalent after dilation was 0.05 diopter (D) more (95% confidence interval [CI], -0.28 to 0.37 D) in the Nanodropper arm, which did not achieve noninferiority. Maximum pupil diameter after dilation was lower in the Nanodropper group (mean, -0.01 mm; 95% CI, -0.20 to -0.03), which did achieve noninferiority. Constriction percentage after dilation was 0.57 percentage points more (95% CI, -1.38 to 2.51 percentage points) in the Nanodropper group, which did not achieve noninferiority. CONCLUSIONS: Administration of eye drops using a small-volume adapter demonstrated similar efficacy to SOC in a pediatric population. Strict noninferiority was met only for pupillary dilation and not for cycloplegia or constriction percentage; however, the small differences in the effect of the Nanodropper versus SOC on all primary outcomes were not clinically significant. We conclude that small-volume eye drops have the potential to decrease unnecessary medical waste and medication toxicity while maintaining therapeutic effect. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Hoppe CB, Yonamine S, Kao BW, et al. Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children. Ophthalmology. 2022. PMID: 36280185. doi:10.1016/j.ophtha.2022.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。